Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhijie Wang(Hubei University of Medicine)
Cited by 28
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Consensus for HER2 alterations testing in non-small-cell lung cancer
|ESMO Open|2022|110
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization
|Nature Communications|2023|70
Detection of <i>MET</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>MET</i> Inhibitors
|Cancer Research Communications|2023|13
Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.
|Journal of Clinical Oncology|2021|5